In focus · trending topic

micro-therapeutics

1 stories · following the connections

Eyenovia, Inc. announces publication of Phase II study results demonstrating benefits of micro-formulation over conventional eyedroppers and addition of Scientific Advisory Board members

By Nasdaq OMXNov 28, 2016, 8:47 PM UTC